A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
- Conditions
- PIK3CA Mutated Advanced Solid TumorsPIK3CA Amplified Advanced Solid Tumors
- Interventions
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT01708161
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 87
- Registration Number
- NCT01705236
- Locations
- 🇨🇭
Novartis Investigative Site, Zuerich, Switzerland
A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 37
- Registration Number
- NCT01703312
- Locations
- 🇸🇪
Novartis Investigative Site, Stockholm, Sweden
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.
- Conditions
- Advanced Solid Tumors, Excluding Breast Cancer
- Interventions
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT01700270
- Locations
- 🇨🇭
Novartis Investigative Site, Genève, Switzerland
🇺🇸Montefiore Medical Center Montefiore Medical Center (SC), Bronx, New York, United States
🇺🇸Cancer Therapy & Research Center / UT Health Science Center SC, San Antonio, Texas, United States
Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.
- Conditions
- Chronic Obstructive Pulmonary Disease: COPD
- Interventions
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 79
- Registration Number
- NCT01699685
- Locations
- 🇨🇭
Novartis Investigative Site, Walenstadtberg, Switzerland
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 163
- Registration Number
- NCT01698905
- Locations
- 🇺🇸
USC Kenneth Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Indiana Blood and Marrow Institute, Beech Grove, Indiana, United States
🇺🇸St Agnes Hospital, Baltimore, Maryland, United States
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
- Conditions
- Hormone Receptor Positive Breast Cancer
- Interventions
- Drug: Standard of care to treat stomatitis (Stomatitis sub-study)
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 202
- Registration Number
- NCT01698918
- Locations
- 🇺🇸
Breastlink Medical Group Dept. of BreastlinkResearchGrp, Long Beach, California, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of Alabama Comprehensive Cancer Center SC-2, Birmingham, Alabama, United States
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 511
- Registration Number
- NCT01697696
- Locations
- 🇺🇸
Novartis Investigative Site, Oregon, Wisconsin, United States
A Phase I Study of Oral BGJ398 in Asian Patients
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT01697605
- Locations
- 🇯🇵
Nagoya University Hospital, Nagoya-city, Aichi, Japan
🇯🇵National Cancer Center Hospital East (NCEE), Kashiwa, Chiba, Japan
🇯🇵Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
- Conditions
- Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
- Interventions
- First Posted Date
- 2012-09-26
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT01693614
- Locations
- 🇺🇸
Memorial Sloan Kettering Dept of Onc., New York, New York, United States
🇺🇸Medical University of South Carolina -Hollings Cancer Center Medical Univ of South Carolina, Charleston, South Carolina, United States
🇹🇷Novartis Investigative Site, Samsun, Turkey